DERM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DE

Mkt Cap

$140.0M

Volume

179.66K

Next Earnings

November 11th

Loading chart

DE

DERMJourney Medical Corporation Common Stock

DERM

Pay with—

Available Balance0.00

DE

Mkt Cap

$140.1M

Volume

179.66K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Are Options Traders Betting on a Big Move in Journey Medical Stock?Journey Medical (DERM) is experiencing elevated implied volatility in its September 2026 $50 call options, suggesting traders expect significant price movement. However, the company holds a Zacks Rank #4 (Sell) rating, with analysts downgrading estimates over the past 60 days, reducing consensus earnings from 9 cents to 2 cents per share. The high volatility may present opportunities for premium-selling strategies rather than bullish positioning.Zacks Investment Research · Sep 21, 2026

Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's LaboratoriesThe global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.GlobeNewswire Inc. · Aug 31, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERMPomerantz LLP is investigating Journey Medical Corporation for potential securities fraud following the company's March 25, 2026 earnings report. Management disclosed that prescription demand for Emrosi exceeded reported revenue due to reimbursement timing and co-pay assistance program usage, with some scripts not being reimbursed. The stock fell 30.01% to $4.78 per share on March 26, 2026, prompting the class action investigation.GlobeNewswire Inc. · Apr 28, 2026

Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute AnalyticaThe global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.GlobeNewswire Inc. · Feb 10, 2026

Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamEmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.GlobeNewswire Inc. · Aug 20, 2025

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaJourney Medical Corporation announced that the FDA has approved Emrosi™, a new treatment for inflammatory lesions of rosacea in adults. The approval is supported by positive data from the company's Phase 3 clinical trials.GlobeNewswire Inc. · Nov 4, 2024

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseSCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.GlobeNewswire Inc. · May 15, 2024

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNew Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024GlobeNewswire Inc. · May 13, 2024

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ETGlobeNewswire Inc. · May 7, 2024

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerSCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company’s Interim Chief Financial Officer since January 2023 and he served as the Company’s Corporate Controller prior to that since November 2021.GlobeNewswire Inc. · May 1, 2024

to start trading

DE

DERMJourney Medical Corporation Common Stock

DERM

Pay with—

Available Balance0.00

Your PositionYou don't own any DERM yet.

Related Tickers

Earnings